{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:44:11Z","timestamp":1792601051264,"version":"4.5.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T00:00:00Z","timestamp":1312243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sclerostin is a secreted Wnt antagonist produced almost exclusively by osteocytes that regulates bone mass. However, there is currently limited information on the determinants of sclerostin in a large population-based study. The main objectives of the present study were to: (1) establish reference normative interval values for serum sclerostin in randomly selected healthy premenopausal women; (2) study the changes in serum sclerostin in relation to age in premenopausal and postmenopausal women and the factors that may influence bone turnover; and (3) determine the effect of menopausal status on serum sclerostin. A total of 1803 women were studied (including [n\u2009=\u20091235] premenopausal, and [n\u2009=\u2009568] postmenopausal women, respectively, aged 20 to 79 years). A total of 443 healthy premenopausal women (aged 35 to 45 years) were used to establish reference normative intervals for serum sclerostin. All women studied were medically examined and had their bone mineral density values obtained for the lumbar spine (L1\u2013L4) and femoral neck according to a detailed inclusion criteria. In all women, values of serum sclerostin increased with increasing age up to the age of 45 years, and remained increased in postmenopausal women. Significant increases were evident in serum sclerostin in postmenopausal women with increasing years since menopause. Using stepwise multiple linear regression analysis, several variables were identified as determinants of serum sclerostin, including age, parathyroid hormone, estradiol (E2), and follicle-stimulating hormone (FSH) for premenopausal women; age, FSH, and E2 for postmenopausal women; and age, serum osteocalcin, FSH, and E2 in the entire sample studied. Further studies are needed to establish the potential role of this increase in mediating the known age-related impairment in bone formation. \u00a9 2011 American Society for Bone and Mineral Research<\/jats:p>","DOI":"10.1002\/jbmr.479","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T20:32:54Z","timestamp":1312317174000},"page":"2812-2822","source":"Crossref","is-referenced-by-count":160,"title":["Determinants of serum sclerostin in healthy pre- and postmenopausal women"],"prefix":"10.1093","volume":"26","author":[{"given":"Mohammed-Salleh M","family":"Ardawi","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine and King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia"},{"name":"Center of Excellence for Osteoporosis Research, Faculty of Medicine and King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan A","family":"Al-Kadi","sequence":"additional","affiliation":[{"name":"Department of Medical Physiology, Faculty of Medicine and King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia"},{"name":"Center of Excellence for Osteoporosis Research, Faculty of Medicine and King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahim A","family":"Rouzi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Faculty of Medicine and King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia"},{"name":"Center of Excellence for Osteoporosis Research, Faculty of Medicine and King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed H","family":"Qari","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine and King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia"},{"name":"Center of Excellence for Osteoporosis Research, Faculty of Medicine and King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,8,2]]},"reference":[{"key":"2024020804155508300_bib1","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/\u03b2-catenin pathway to regulate bone formation in the adults skeleton","volume":"148","author":"Barons","year":"2007","journal-title":"Endocrinology."},{"key":"2024020804155508300_bib2","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI28551","article-title":"Regulation of bone mass by Wnt signaling","volume":"116","author":"Krishnan","year":"2006","journal-title":"J Clin Invest."},{"key":"2024020804155508300_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.14310\/horm.2002.1111024","article-title":"The role of the Wnt signaling pathway in osteoblast commitment and differentiation","volume":"6","author":"Yavropoulou","year":"2007","journal-title":"Hormones (Athens)."},{"key":"2024020804155508300_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","article-title":"Wnt\/\u03b2-catenin signaling in development and disease","volume":"127","author":"Clevers","year":"2006","journal-title":"Cell."},{"key":"2024020804155508300_bib5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/BOR.0b013e32816e06f9","article-title":"The Wnt signaling pathway and bone metabolism","volume":"19","author":"Johnson","year":"2007","journal-title":"Curr Opin Rheumatol."},{"key":"2024020804155508300_bib6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1242\/jcs.02883","article-title":"Wnt signaling in osteoblasts regulates expression of the receptor activator of NF\u03baB ligand and inhibits osteoclastogenesis in vitro","volume":"119","author":"Spencer","year":"2006","journal-title":"J Cell Sci."},{"key":"2024020804155508300_bib7","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1242\/dev.01117","article-title":"LDL receptor-related proteins 5 and 6 in Wnt\/\u03b2-catenin signaling: arrows point the way","volume":"131","author":"He","year":"2004","journal-title":"Development."},{"key":"2024020804155508300_bib8","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Semenov","year":"2005","journal-title":"J Biol Chem."},{"key":"2024020804155508300_bib9","first-page":"1738","article-title":"Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5\/6 and antagonizes canonical Wnt signaling","volume":"21","author":"Ellies","year":"2006","journal-title":"J Biol Chem."},{"key":"2024020804155508300_bib10","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem."},{"key":"2024020804155508300_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet."},{"key":"2024020804155508300_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum Mol Genet."},{"key":"2024020804155508300_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","article-title":"A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population","volume":"110","author":"Staehling-Hampton","year":"2002","journal-title":"Am J Med Genet."},{"key":"2024020804155508300_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J Med Genet."},{"issue":"6","key":"2024020804155508300_bib15","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024020804155508300_bib16","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel of BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J."},{"issue":"4","key":"2024020804155508300_bib17","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2024020804155508300_bib18","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024020804155508300_bib19","author":"Ke"},{"key":"2024020804155508300_bib20","first-page":"580","article-title":"Increased bone formation and bone mass by sclerostin antibody was not blunted by pretreatment with alendronate in ovariectomized rats with established osteopenia","author":"Li","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024020804155508300_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020804155508300_bib22","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/jc.2009-2283","article-title":"Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women","volume":"95","author":"Mirza","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024020804155508300_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men","volume":"26","author":"Modder","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020804155508300_bib24","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1210\/jc.2010-0067","article-title":"Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss","volume":"95","author":"Gaudio","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020804155508300_bib25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bone.2010.07.017","article-title":"Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study","volume":"47","author":"Ardawi","year":"2010","journal-title":"Bone."},{"key":"2024020804155508300_bib26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4065\/81.3.353","article-title":"High prevalence of vitamin D inadequacy and implications for health","volume":"81","author":"Holick","year":"2006","journal-title":"Mayo Clin Proc."},{"key":"2024020804155508300_bib27","author":"World Health Organization"},{"key":"2024020804155508300_bib28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally weighted regression and smoothing scatterplots","volume":"74","author":"Cleveland","year":"1979","journal-title":"JA Stat Assoc."},{"key":"2024020804155508300_bib29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2007.12.218","article-title":"Establishing a reference range for bone turnover markers in young, healthy women","volume":"42","author":"Glover","year":"2008","journal-title":"Bone."},{"key":"2024020804155508300_bib30","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J Exp Med."},{"key":"2024020804155508300_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cytogfr.2005.02.005","article-title":"SOST\/sclerostin, an osteocyte-derived negative regulator of bone formation","volume":"16","author":"van Bezooijen","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"2024020804155508300_bib32","article-title":"Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women\u2014the six-month effect of risedronate and teriparatide","author":"Polyzos","year":"2011","journal-title":"Osteoporos Int."},{"key":"2024020804155508300_bib33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","article-title":"Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res."},{"key":"2024020804155508300_bib34","first-page":"281","article-title":"Inhibin A and B as markers of menopause: a five-year prospective longitudinal study of hormonal changes during the menopausal transition","volume":"84","author":"Overlie","year":"2005","journal-title":"Acta Obstet Gynecol Scand."},{"key":"2024020804155508300_bib35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s001980200043","article-title":"Bone mass, bone metabolism, gonadal status and body mass index","volume":"13","author":"Rico","year":"2002","journal-title":"Osteoporos Int."},{"key":"2024020804155508300_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S8756-3282(02)00864-5","article-title":"Relationships among body mass, its components and bone","volume":"31","author":"Reid","year":"2002","journal-title":"Bone."},{"key":"2024020804155508300_bib37","first-page":"4025","article-title":"Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women","volume":"84","author":"Burger","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020804155508300_bib38","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1007\/s00198-005-1871-y","article-title":"Osteoporosis assessment by whole body region vs. site-specific DXA","volume":"16","author":"Melton","year":"2005","journal-title":"Osteoporos Int."},{"key":"2024020804155508300_bib39","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1210\/jc.2002-020777","article-title":"Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size and menopausal status","volume":"88","author":"Randolph","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020804155508300_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00198-009-0943-9","article-title":"Age-related changes in biochemical markers of bone turnover and gonadotropin levels and their relationship among Chinese adult women","volume":"21","author":"Wu","year":"2010","journal-title":"Osteoporos Int."},{"key":"2024020804155508300_bib41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.maturitas.2005.01.009","article-title":"Ovarian aging and bone metabolism in menstruating women aged 35\u201350 years","volume":"52","author":"Vural","year":"2005","journal-title":"Maturitas."},{"key":"2024020804155508300_bib42","doi-asserted-by":"crossref","first-page":"14925","DOI":"10.1073\/pnas.0606805103","article-title":"Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblasts and osteoclast formation","volume":"103","author":"Iqbal","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"2024020804155508300_bib43","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1196\/annals.1402.056","article-title":"Prospective actions of FSH and bone loss","volume":"116","author":"Zaidi","year":"2007","journal-title":"Ann NY Acad Sci."},{"issue":"11","key":"2024020804155508300_bib44","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1210\/jc.2010-1103","article-title":"Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women","volume":"95","author":"Drake","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2024020804155508300_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jbmr.128","article-title":"Regulation of circulating sclerostin levels by sex steroids in women and men","volume":"26","author":"Modder","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020804155508300_bib46","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a noval mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology."},{"key":"2024020804155508300_bib47","doi-asserted-by":"crossref","first-page":"e2942","DOI":"10.1371\/journal.pone.0002942","article-title":"Control of bone mass and remodeling by PTH receptor signaling in osteocytes","volume":"3","author":"O'Brien","year":"2008","journal-title":"PLoS ONE."},{"key":"2024020804155508300_bib48","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1530\/EJE-10-0699","article-title":"Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls","volume":"163","author":"van Lierop","year":"2010","journal-title":"Euro J Endocrinol."},{"issue":"11","key":"2024020804155508300_bib49","first-page":"5056","article-title":"Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women","volume":"95","author":"Drake","year":"2010","journal-title":"J Bone Miner Res."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.479","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/26\/12\/2812\/56557884\/479_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/26\/12\/2812\/56557884\/479_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:47:09Z","timestamp":1710341229000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/26\/12\/2812-2822\/7597942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,2]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,8,2]]},"published-print":{"date-parts":[[2011,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.479","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,12,1]]},"published":{"date-parts":[[2011,8,2]]}}}